Chemotherapy for cranial base tumors.
The tumors I will discuss in this chapter on chemotherapy will be ethesioneuroblastoma, salivary gland tumors, chordoma and nasopharyngeal carcinoma. Due basically to the rarity of these lesions, with the exception of nasopharyngeal carcinoma, there have been no multi-institutional studies of chemotherapy use reported in the literature. As a result, there is no clear-cut consensus on the standard of care as it relates to chemotherapy for these tumors. As with most authors who have previously reviewed these tumor types, I believe it is important for us to propose protocols of therapy and test these in arenas where we can accumulate enough patients for meaningful results. In this way, we can test the apparently active agents and combinations in relapsed or extensive disease. We might also begin to explore concurrent therapy (i.e., concurrent radiation and chemotherapy after the surgical procedure, for example).
Jacob
H E
HE
University of Pittsburgh, Department of Anesthesiology and Critical Care Medicine, PA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant; D002817:Chordoma / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018304:Esthesioneuroblastoma, Olfactory / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D009296:Nasal Cavity; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012468:Salivary Gland Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents